Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Our ambition is to empower our customers to improve and extend their health span through testing, teaching, and transforming health, so they can prevent adverse chronic health conditions before they begin
The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016) showed a 26% reduction in major adverse cardiovascular events (MACE) with subcutaneous semaglutide vs placebo in patients with type 2 diabetes and high cardiovascular risk
I went and got a prescription and I got Ozempic
To maximize sample sizes whilst aligning with guideline-recommended target populations for these therapies, different whose patient characteristics were independently well-matched: (1) CV outcomes among people with T2D and ASCVD, (2) glucose and weight outcomes among people with T2D, and (3) renal outcomes in people with T2D and CKD [6]
Studies show that semaglutide may help protect the kidneys, especially in patients with renal impairment and those at risk for heart failure
